Platelet aggregation at discharge: A useful tool in acute coronary syndromes?

Revista Portuguesa de Cardiologia

Volumn 31, Issue 9, 2012, Pages 545-554

  Teixeira, Rogério ^a   Monteiro, Pedro ^a   Marques, Gilberto ^a   Pego, João Mariano ^a   Lourenço, Margarida ^a   Tavares, Carlos ^a   Reboredo, Alda ^a   Monteiro, Sílvia ^a   Gonçalves, Francisco ^a   Ferreira, Maria J ^a   Freitas, Mário ^a   Ribeiro, Graça ^a   Providência, Luís A ^a  

^a CENTRO HOSPITALAR E UNIVERSITÁRIO DE COIMBRA   (Portugal)

Author keywords

Acute coronary syndromes; Platelet aggregation; Prognosis

Indexed keywords

ACETYLSALICYLIC ACID; ANTICOAGULANT AGENT; ANTITHROMBOCYTIC AGENT; C REACTIVE PROTEIN; CLOPIDOGREL; HEMOGLOBIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; PRASUGREL; PROTON PUMP INHIBITOR; TROPONIN I;

ACUTE CORONARY SYNDROME; ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; BLOOD CLOTTING PARAMETERS; CORONARY HEMODYNAMICS; DEMOGRAPHY; EVENT FREE SURVIVAL; FEMALE; FOLLOW UP; GENOTYPE; HEART INFARCTION; HOSPITAL ADMISSION; HOSPITAL DISCHARGE; HUMAN; LENGTH OF STAY; LOADING DRUG DOSE; LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; MALE; MEDICAL HISTORY; MORTALITY; POLYMERASE CHAIN REACTION; PREDICTIVE VALUE; PROGNOSIS; PROSPECTIVE STUDY; SCORING SYSTEM; ST SEGMENT DEPRESSION; ST SEGMENT ELEVATION MYOCARDIAL INFARCTION; THROMBOCYTE ADHESION; THROMBOCYTE AGGREGATION; UNSTABLE ANGINA PECTORIS;

EID: 84867578671     PISSN: 08702551     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.repc.2012.06.005     Document Type: Article

References (35)

1. Yusuf S, Zhao F, Mehta S, et al. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. The Clopidogrel in Unstable Angina to Prevent Recurrent Events Trial Investigators. N Engl J Med. 2001;345:494-502. (Pubitemid 32758501)
2. Steinhubl S, Berger P, Mann III J, et al. Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial - Clopidogrel for the Reduction of Events During Observation. JAMA. 2002;288:2411-20. (Pubitemid 35340537)
3. Gurbel P, Blinden K, Hiatt B, et al. Clopidogrel for coronary stenting: response variability, drug resistance, and the effect of pretreatment platelet reactivity. Circulation. 2003;107:2908-13. (Pubitemid 36736631)
4. Snoep J, Hovens M, Eikenboom J, et al. Clopidogrel nonresponsiveness in patients undergoing percutaneous coronary intervention with stenting: a systematic review and meta-analysis. Am Heart J. 2007;154:221-31. (Pubitemid 47069129)
5. Sibbing D, Braun S, Jawansky S, et al. Platelet reactivity after clopidogrel treatment assessed with point of care analysis and early drug-eluting stents. J Am Coll Cardiol. 2009;53:849-56.
6. Bonello L, Paganelli F, Arpin-Bornet M, et al. Vasodilator-stimulated phosphoprotein phosphorylation analysis prior to percutaneous coronary intervention for exclusion of postprocedural major adverse cardiovascular events. J Thromb Haemost. 2007;5:1630-6. (Pubitemid 47091403)
7. Hochholzer W, Trenk D, Bestehorn H, et al. Impact of the degree of peri-interventional platelet inhibition after loading with clopidogrel on early clinical outcome of elective coronary stent placement. J Am Coll Cardiol. 2006;48:1742-50. (Pubitemid 44648629)
8. Denninger M, Necciari J, Seere Lacroix E, et al. Clopidogrel antiplatelet activity is independent of age and presence of atherosclerosis. Semin Thromb Hemost. 1999;25:41-5. (Pubitemid 29350291)
9. Dynabyte informatiossysteme GmbH website. Available at: www.multiplate.net. Accessed September 16, 2010.
10. Sibbing D, Braun S, Jawansky S, et al. Assessment of ADP-induced platelet aggregation with light transmission aggregometry and multiple electrode platelet aggregometry before and after clopidogrel treatment. Thromb Haemost. 2008;99:121-6.
11. *CER) trial: study design and rationale. Am Heart J. 2009;158:327-34.
12. Chin T, Roe M, Fox K, et al. For the TRILOGY ACS Steering Committee, Study design and rationale of a comparison of prasugrel and clopidogrel in medically managed patients with unstable angina/non ST segment elevation myocardial infarction: the TaRgeted platelet Inhibition to cLarify the Optimal strateGy to medicallY manage Acute Coronary Syndromes (TRILOGY ACS) trial. Am Heart J. 2010;1:16-22.
13. Thygesen K, Alpert J, White H, on behalf of the Joint ESC/ACCF/AHA/WHF Task Force for the Redefinition of Myocardial Infarction. Universal definition of myocardial infarction. Eur Heart J. 2007;28:2525-38. (Pubitemid 47616190)
14. Anderson J, Adams C, Antman E, et al. ACC/AHA 2007 guidelines for the management of patients with unstable angina/non-ST-elevation myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to revise the 2002 Guidelines for the Management of Patients with Unstable Angina/Non-ST-Elevation Myocardial Infarction): developed in collaboration with the American College of Emergency Physicians, American College of Physicians, Society for Academic Emergency Medicine, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons. J Am Coll Cardiol. 2007;116:e148-304.
15. Mueller T, Dieplinger B, Poelz W, et al. Utility of whole blood impedance aggregometry for the assessment of clopidogrel action using the novel Multiplate (r) analyzer - comparison with two flow cytometric methods. Thromb Res. 2007;121:249-58. (Pubitemid 350148206)
16. Toth O, Calatzis A, Penz S, et al. Multiple electrode aggregometry: a new device to measure platelet aggregation in whole blood. Thromb Haemost. 2006;96:781-8. (Pubitemid 44883819)
17. Chun J, Kim K, Hwang I, et al. Dual priming oligonucleotide system for the multiplex detection of respiratory viruses and SNP genotyping of CYP2C19 gene. Nucleic Acids Res. 2007;35:e40-6.
18. Gurbel P, Becker R, Mann K, et al. Platelet function monitoring in patients with coronary artery disease. J Am Coll Cardiol. 2007;50:1822-34. (Pubitemid 350007957)
19. Khalique S, McGowan J, Levy R, et al. Monitoring antiplatelet therapy in patients undergoing percutaneous coronary intervention: comparison of VerifyNow and Multiplate. Pathophysiol Haemost Thromb. 2008;36 Suppl. 1:P039.
20. Bouchard B, Tracy P. Platelets, leukocytes and coagulation. Curr Opin Hematol. 2001;8:263-9.
21. Bonello L, Tantry U, Marcucc R, et al., For the Working Group on High On-Treatment Platelet Reactivity. Consensus and future directions on the definition of high on-treatment platelet reactivity to adenosine diphosphate. J Am Coll Cardiol. 2010;56:920-33.
22. Price M. Bedside evaluation of thienopyridine antiplatelet therapy. Circulation. 2009;119:2625-32.
23. Miguel Castro A, Cuellas R, Neto, et al. Post-treatment platelet reactivity predicts long-term adverse events better than the response to clopidogrel in patients with non-ST-segment elevation acute coronary syndrome. Rev Esp Cardiol. 2009;62:126-35.
24. Teixeira R, Lourenço C, Baptista R, et al. Invasive versus conservative strategy in non-ST elevation acute coronary syndromes: data from a single Portuguese center. Rev Port Cardiol. 2009;28:355-73.
25. Tantry U, Blinden K, Gurbel P. What is the best measure of thrombotic risks-pretreatment platelet aggregation, clopidogrel responsiveness, or posttreatment platelet aggregation? Catheter Cardiovasc Interv. 2005;66:597-8. (Pubitemid 41779035)
26. Libby P. Current concepts of the pathogenesis of the acute coronary syndromes. Circulation. 2001;104:365-72. (Pubitemid 32666962)
27. Vandendries E, Furie BC, Furie B. Role of P-selectin and PSGL-1 in coagulation and thrombosis. Thromb Haemost. 2004;92:459-66. (Pubitemid 39248002)
28. Nissen S. High-dose statins in acute coronary syndromes: not just lipid levels. JAMA. 2004;292:1365-7. (Pubitemid 39223231)
29. Rosenson R. Pluripotential mechanisms of cardioprotection with HMG-CoA reductase inhibitor therapy. Am J Cardiovasc Drugs. 2001;1:411-20.
30. Mega J, Tabassome S, Collet J, et al. Reduced-function CYP2C19 genotype and risk of adverse clinical outcomes among patients treated with clopidogrel predominantly for PCI. JAMA. 2010;304:1821-30.
31. TRITON-TIMI 38 Investigators. Prasugrel versus clopidogrel in patients with acute coronary syndromes. N Engl J Med. 2007;95:2001-15.
32. Wallentin L, Becker R, Budaj A, et al. Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N Engl J Med. 2000;361:1045-57.
33. Brar S, Berg J, Marcucci R, et al. Impact of platelet reactivity on clinical outcomes after percutaneous coronary intervention: a collaborative meta-analysis of individual participant data. J Am Coll Cardiol. 2011;58:1945-54.
34. Price J, Berger P, Teirstein S, et al. Standard vs. high-dose clopidogrel based on platelet function testing after percutaneous coronary intervention. JAMA. 2011;305:1097-105.
35. Kuliczkowski W, Witkowski A, Poloonski L, et al. Interindividual variability in the response to oral antiplatelet drugs: a position paper of the Working Group on antiplatelet drugs resistance appointed by the Section of Cardiovascular Interventions of the Polish Cardiac Society, endorsed by the Working Group on Thrombosis of the European Society of Cardiology. Eur Heart J. 2009;30:426-35.